June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
The Fibronectin-Derived Peptide PHSRN Promotes Corneal Epithelial Wound Healing in Diabetic Rats
Author Affiliations & Notes
  • Naoyuki Morishige
    Division of Cornea and Ocular Surface, Ohshima Hospital of Ophthalmology, Fukuoka, Fukuoka, Japan
    Yamaguchi University, Ube, Japan
  • Aiko Uemura
    Yamaguchi University, Ube, Japan
  • Yukiko Morita
    Yamaguchi University, Ube, Japan
  • Teruo Nishida
    Division of Cornea and Ocular Surface, Ohshima Hospital of Ophthalmology, Fukuoka, Fukuoka, Japan
  • Footnotes
    Commercial Relationships   Naoyuki Morishige, None; Aiko Uemura, None; Yukiko Morita, None; Teruo Nishida, US patent 8207119 (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2617. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Naoyuki Morishige, Aiko Uemura, Yukiko Morita, Teruo Nishida; The Fibronectin-Derived Peptide PHSRN Promotes Corneal Epithelial Wound Healing in Diabetic Rats. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2617.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Topical application of the fibronectin-derived peptide PHSRN has previously been shown to facilitate corneal epithelial wound healing in healthy animals as well as in patients with persistent epithelial defects. We have now examined the effect of PHSRN eyedrops on the healing of corneal epithelial wounds in rats with streptozotocin-induced diabetes.

Methods : Four-week-old Wistar rats were injected intraperitoneally with streptozotocin (70 mg/kg, n = 12) or vehicle (n = 8). Four weeks after confirmation of the presence or absence of glycosuria, a 3-mm-diameter portion of the corneal epithelium of the right eye was excised. Eyedrops containing PHSRN (200 µM) or phosphate-buffered saline (PBS) vehicle were administered to the injured eye of the diabetic or nondiabetic animals every 6 h. The epithelial defect as revealed by fluorescein staining was also photographed every 6 h. For evaluation of the effect of PHSRN at different doses, eyedrops containing 0, 2, 20, or 200 µM peptide were applied to the corneal defect of diabetic rats every 6 h and the defect was photographed at 0 and 18 h. The area of epithelial defects was determined from photographs with the use of Image J software.

Results : The area of the epithelial defect did not differ significantly among the four experimental groups (diabetic or control rats treated with PHSRN or vehicle) at 12 h after wounding. At 18 h, however, the area of the defect in diabetic rats treated with PHSRN (0.50 ± 0.34 mm2) was significantly (P < 0.05) smaller than that in diabetic rats treated with PBS (1.06 ± 0.42 mm2) and was similar to that in nondiabetic rats treated with PBS (0.60 ± 0.23 mm2). The decrease in size of the epithelial defect in diabetic rats treated with PHSRN was dependent on the dose of the peptide.

Conclusions : The administration of PHSRN eyedrops significantly facilitated the healing of corneal epithelial wounds in diabetic rats. Our data therefore suggest that PHSRN eyedrops warrant investigation as a promising treatment option for patients with diabetic keratopathy.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×